SEARCH

SEARCH BY CITATION

References

  • 1
    Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992; 15: 567571.
  • 2
    Bach N, Thung SH, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15: 572577.
  • 3
    Lefkowitch JH, Schiff ER, Davis GL, Perrilo RP, Lindsay K, Bodenheimer HC, Balart LA. et al. Pathological diagnosis of chronic hepatitis C. A multicenter comparative study with chronic hepatitis B. Gastroenterology 1993; 104: 595603.
  • 4
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372374.
  • 5
    Ludwig J. The nomenclature of chronic active hepatitis: an obituary. Gastroenterology 1993; 105: 274278.
  • 6
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 15131519.
  • 7
    Scheuer PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995; 22: 112114.
  • 8
    The METAVIR cooperative group. Inter-and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994;20; 1: 1520.
  • 9
    Liaw Y-F, Tai D-I, Chu C-M, Chen T-J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493496.
  • 10
    Knodell KG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW. et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431435.
  • 11
    Poynard T, Bedossa P, Delfraissy JF, Naveau S, Lemaigre G, Chaput JC. Efficacy of low doses, long term alpha recombinant interferon in patients with chronic C hepatitis: Clinical biological histological and immunohisto-chemical study. Gastroenterol Clin Biol 1991; 15: 615619.
  • 12
    Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C. and A multicenter study group. Improvement of histological lesions by 18 months therapy with a2B interferon in patients with chronic hepatitis C. A randomized clinical trial. N Engl J Med 1995; 22: 14571462.
  • 13
    Valla D, Babany G, Ouzan D, Trepo C, Bourliere M, Gales P, Payen JL. et al. Prevention of relapse in patients with chronic non A. non B/C hepatitis who respond to alpha-interferon. A controlled multicenter trial of low-dose maintenance therapy. J Hepatol 1994; 21: 774778.
  • 14
    Ouzan D, Skaf R, Andreani T, Opolon P, Trepo C, Michel P, Couzigou P. French multicenter control trial of interferon alpha 2a (IFN) in chronic hepatitis C. Does an attack dose (6MU) increase the response rate at 6 and 12 months [Abstract]. J Hepatol 1993; 18S: 53.
  • 15
    Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM. Comparative efficacy of interferon alpha in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994; 106: 686690.
  • 16
    METAVIR. Proposition d'une grille de recueil des lesions histopathologiques dans l'Tiépatite chronique viral. C. Ann Pathol 1993; 13: 260265.
  • 17
    Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type Ib infection in France and Italy. Collaborative study group. Ann Intern Med 1995; 122: 161168.
  • 18
    Theodossi A, Skene AM, Portmann B, Knill-Jones RP, Patrick RS, Tate RA, Kealey W. et al. Observer variation in assessment of liver biopsies including analysis by Kappa statistics. Gastroenterology 1980; 79: 232241.